Posted on 12/01/2010 in Pharmaceutical Company Product News Abbott announced this week that its colorectal cancer test, the RealTime mS9, has been granted CE marking in the European Union.
The product is a non-invasive DNA assay that detects the methylated form of Septin 9 in blood specimens - a gene linked to colorectal cancer.
During several clinical trials, the new system picked up on 70 per cent of cancers in all disease stages at 90 per cent specificity.
The test, which is the first automated assay for detecting the Septin 9 gene in plasma, provides physicians with a tool to help them determine whether a patient should be referred for a colonoscopy.
Stafford O'Kelly, head of Abbott's molecular diagnostics business, commented: "Convenience has been a major limitation of current colorectal cancer screening methods and the blood test addresses these long-standing concerns."
In other Abbott news, the firm announced that it will acquire STARLIMS Technologies last month, a move that will cost the organisation $123 million (75.7 million pounds).Other news stories from 12/01/2010
Read more in the Zenopa News Archive
How this news is generated
|
